During the past decade, Schwarzwald-Baar Klinikum conducted 34 clinical trials. In the 10-year time frame, 34 clinical trials started and 13 clinical trials were completed, i.e. on average, 38.2% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 7 clinical trials were completed. i.e. 63.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Schwarzwald-Baar Klinikum" #1 sponsor was "University of Ulm" with 8 trials, followed by "Abbott Medical Devices" with 6 trials sponsored, "Biotronik SE & Co. KG" with 4 trials sponsored, "IHF GmbH - Institut für Herzinfarktforschung" with 4 trials sponsored and "Celgene" with 4 trials sponsored. Other sponsors include 42 different institutions and companies that sponsored additional 43 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Schwarzwald-Baar Klinikum" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)" with 2 trials as a collaborator, "ETOP IBCSG Partners Foundation" with 2 trials as a collaborator, "Medtronic" with 2 trials as a collaborator and "Novartis Pharmaceuticals" with 2 trials as a collaborator. Other collaborators include 37 different institutions and companies that were collaborators in the rest 45 trials.

According to Clinical.Site data, the most researched conditions in "Schwarzwald-Baar Klinikum" are "Acute Myeloid Leukemia" (7 trials), "Heart Failure" (6 trials), "Acute Myeloid Leukemia (AML)" (4 trials), "Atrial Fibrillation" (4 trials) and "Acute Coronary Syndrome" (3 trials). Many other conditions were trialed in "Schwarzwald-Baar Klinikum" in a lesser frequency.

Most popular intervention types in "Schwarzwald-Baar Klinikum" are "Drug" (40 trials), "Device" (21 trials), "Biological" (4 trials), "Procedure" (4 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Cytarabine" (6 trials), "Placebo" (6 trials), "Carboplatin" (3 trials), "Daunorubicin" (3 trials) and "Rituximab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Schwarzwald-Baar Klinikum" are 68 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Schwarzwald-Baar Klinikum". undefined are not yet recruiting, 8 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 39 completed trials in Schwarzwald-Baar Klinikum, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Schwarzwald-Baar Klinikum, 1 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 7 trials that are defined as “Not Applicable".

Schwarzwald-Baar Klinikum has several departments that took part in Clinical trials: "Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie" - 7 trials